Data presented at ASCO demonstrated the value of the Integra Connect database – which includes de-identified claims and clinical records for community-based oncology practices across the United States. The study showed that patients with stage 4 non-small cell lung cancer who received targeted treatment from the outset had a survival exceeding 800 days vs. 672 days in those who switched to the appropriate targeted agents within 35 days and 435 days in those who did not switch within this timeframe.Read more
Why Integra Connect?
We transform data into knowledge.
65+ engagements with top pharma, medtech and biotech companies
Established the industry’s largest foothold into oncology practices focused on VBC, with more than 5,000 providers supported
60+ scientific publications demonstrating the value of our data and solutions over the past two years
WE ARE OBSSESSED WITH YOUR SUCCESS.
Book a demo to see what we can do for you.
Sign up to receive a free demo customized to you and your organization’s needs. An Integra Connect Specialist will reach out to schedule it and complete the process.